03 Sep NYU: GLP-1 Receptor Agonists and Hair Loss: What a Mendelian Randomization Study Reveals About Genetic Risk
MedicalResearch.com Interview with:
Lynn Petukhova, PhD
Assistant Professor, Ronald O. Perelman Department of Dermatology
Assistant Professor, Department of Population Health
NYU Grossman School of Medicine
NYU Langone Health
Dr. Petukhova[/caption]
MedicalResearch.com: What is the background for this study? What are the main findings?
Dr. Petukhova: As GLP-1 receptor agonists such as Ozempic and Wegovy are increasingly used for type 2 diabetes and weight loss, questions have emerged about whether these medications may be linked to hair loss. Some cases may reflect telogen effluvium, a temporary shedding that can occur after rapid weight loss or major metabolic stress. However, recent observational studies have suggested there may also be a link with androgenetic alopecia, or patterned hair loss, in some individuals. According to the National Institute of Diabetes and Digestive and Kidney Diseases, GLP-1 receptor agonists are among the most prescribed medication classes for type 2 diabetes and obesity management, making the safety and side effect profile of these drugs a growing area of clinical research. Watch the interview in Video format
Dr. Don Kikkawa[/caption]
Dr. Leo Miller[/caption]
Dr. Adalja[/caption]